Genetic Technologies

Genetic Technologies Liabilities

The Liabilities of Genetic Technologies (GTG.AX) as of Oct 27, 2026.

Liabilities

0.00AUD

Last updated:

In 2025, Genetic Technologies's total liabilities amounted to 0.00 AUD, a % difference from the 4.36 M AUD total liabilities in the previous year.

The Genetic Technologies Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
1.45 M AUD
Jan 1, 2019
1.49 M AUD
Jan 1, 2020
1.64 M AUD
Jan 1, 2021
1.44 M AUD
Jan 1, 2022
4.37 M AUD
Jan 1, 2023
3.69 M AUD
Jan 1, 2024
4.36 M AUD
Jan 1, 2025
0.00 AUD
The Genetic Technologies Liabilities history
YEARLiabilitiesYoY
0.00AUD-100.00%
4.36 MAUD+17.93%
3.69 MAUD-15.49%
4.37 MAUD+203.80%
1.44 MAUD-12.30%
1.64 MAUD+9.81%
1.49 MAUD+2.73%
1.45 MAUD-4.91%
1.53 MAUD+8.73%
1.41 MAUD-20.11%
1.76 MAUD-64.08%
4.90 MAUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genetic Technologies Stock analysis

What does Genetic Technologies do? Genetic Technologies Ltd is an Australian biotechnology company that was founded in 1989. The company is an internationally recognized provider of genomic analysis procedures and technologies and has been operating in various business sectors since its establishment. Genetic Technologies is headquartered in Melbourne, Australia, and maintains offices in the USA, Europe, and Asia. The company's business model is based on the development and commercialization of genetic analysis systems and technologies. Genetic Technologies serves a wide range of customers, including research institutes, universities, diagnostic laboratories, biotechnology companies, and pharmaceutical companies. The company specializes in the analysis of DNA sequences and offers various genetic testing procedures to, for example, identify genetic risk factors for certain diseases or determine the ancestry of individuals. Genetic Technologies' different business sectors include clinical diagnostics, agriculture, forensic science, and scientific research. The company develops and markets various genetic testing procedures, such as the BREVAGenplus test, which aims to help women determine their risk for breast and ovarian cancer. Genetic Technologies also plays a leading role in agriculture, offering, for example, the CalfStart test, which allows breeders to determine the genetic potential of their calves. In forensic science, Genetic Technologies develops DNA tests that help solve criminal cases and identify perpetrators. Furthermore, the company also provides genetic counseling services. Another important area of Genetic Technologies is the development and commercialization of genetic analysis procedures and technologies. The company holds several patents worldwide for DNA analysis procedures, including the patented non-coding procedure, which represented a significant breakthrough in genomic research. Genetic Technologies' chairman, Dr. Mervyn Jacobson, is a recognized expert in the field of genomic research and has already authored numerous scientific publications on this topic. In addition to its various business sectors and products, Genetic Technologies has also established close relationships with other companies and institutions in the biotechnology industry. For example, the company collaborates closely with the USA-based HudsonAlpha Institute for Biotechnology to jointly develop innovative DNA technologies and procedures. Overall, Genetic Technologies has made a name for itself as a company specializing in the analysis of DNA sequences. Through its innovative products and services, the company has contributed to advancing genomic research and gaining new insights into the genetic basis of diseases and other phenomena. With its broad range of business sectors and international presence, Genetic Technologies is an important player in the biotechnology industry and is likely to further expand in the coming years. Genetic Technologies is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Genetic Technologies's Liabilities

Genetic Technologies's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Genetic Technologies's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Genetic Technologies's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Genetic Technologies's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Genetic Technologies’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Genetic Technologies stock

On Eulerpool you can find the complete historical development of The Liabilities Genetic Technologies since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Genetic Technologies historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Genetic Technologies

All Key Metrics — Genetic Technologies